Pfizer announces positive top-line results from PALOMA-1 evaluating Palbociclib plus letrozole in women with advanced breast cancer
3 February 2014 | By Pfizer
Clinical benefit demonstrated for potential first-in-class CDK 4 and 6 inhibitor...
List view / Grid view
News
Tecfidera® (dimethyl fumarate) approved in the European Union as a first-line oral treatment for multiple sclerosis
3 February 2014 | By Biogen Idec
Biogen Idec to begin launching TECFIDERA in initial EU Countries in the coming weeks...
GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe aplastic anaemia
3 February 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the FDA has granted Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for the treatment of cytopenias...
AstraZeneca completes the acquisition of Bristol-Myers Squibb share of global diabetes alliance
3 February 2014 | By AstraZeneca
AstraZeneca announced that it completed, on 1 February 2014, the acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance...
Suven Life secures three product patents for their NCEs in Canada, China and India
31 January 2014 | By Suven Life Sciences Ltd
Suven announces that the grant of three product patents one each from Canada, China and India corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through through 2025...
Edison Pharma and Dainippon Sumitomo Pharma (DSP) enter $4 billion metablosim drug deal
31 January 2014 | By Edison Pharmaceuticals
Novel partnership in drugs targeting biological energy...
Abbvie completes largest phase iii program of an all-oral, interferon-free therapy for the treatment of hepatitis c genotype 1
31 January 2014 | By AbbVie
AbbVie announced the completion of its phase III clinical program and released results of four additional studies designed to assess AbbVie's investigational all-oral, interferon-free therapy...
Roche delivers strong 2013 results
30 January 2014 | By Roche
Roche’s CEO Severin Schwan: “2013 was a very good year for Roche. We exceeded our financial targets with strong demand for our existing products and positive uptake of recently launched medicines and diagnostics...
Biogen Idec and UCB enter agreements to commercialize multiple sclerosis and hemophilia therapies in Asia
30 January 2014 | By Biogen Idec
Relationship leverages UCB’s expertise and presence in Asia to bring Biogen Idec’s Innovative therapies to patients in new markets...
Amgen announces positive top-line results from Phase 3 RUTHERFORD-2 trial of evolocumab in patients with heterozygous familial hypercholesterolemia
30 January 2014 | By Amgen
RUTHERFORD-2 study meets co-primary endpoints of ldl cholesterol reduction Amgen also announces results from phase 3 study with automated mini-doser completion of fifth phase 3 study forms basis for global filing plan...
Teva announces U.S. FDA approval of three-times-a-week COPAXONE® 40mg/mL
28 January 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced that the FDA has approved the Company’s supplemental new drug application for three-times-a-week COPAXONE® 40mg/mL...
Merck statement on FDA Advisory Committee meeting for RAGWITEK™, an investigational sublingual allergy immunotherapy tablet
28 January 2014 | By Merck
Merck said it was pleased with the positive discussion of RAGWITEK™ at the Allergenic Products Advisory Committee meeting of the U.S. Food and Drug Administration...
Tecan offers Cavro® air displacement pipettor option for Cavro Omni Robot
28 January 2014 | By kdm communications limited
Tecan has introduced a Cavro® ADP (Air Displacement Pipettor) module for the popular Cavro Omni Robot...
Amgen announces positive top-line results from Phase 3 LAPLACE-2 trial of Evolocumab (AMG 145) in combination with statins in patients with high cholesterol
28 January 2014 | By Amgen
Amgen announced that the Phase 3 LAPLACE-2 trial evaluating evolocumab in combination with statin therapy in patients with high cholesterol met its co-primary endpoints...
Live cellular FRET fluorescent protein assay (mTFP-YFP) – No filters needed
28 January 2014 | By BMG LABTECH
When adapting a fluorescent protein assay from a confocal microscope to a microplate format, researchers no longer need filters thanks to new LVF Monochromators™ in the CLARIOstar® microplate reader from BMG LABTECH...
